These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 12559811)

  • 1. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
    Sukumaran B; Tewary P; Saxena S; Madhubala R
    Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leishmaniasis: current status of vaccine development.
    Sukumaran B; Madhubala R
    Curr Mol Med; 2004 Sep; 4(6):667-79. PubMed ID: 15357215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
    Sharma A; Madhubala R
    J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.
    Ghosh A; Zhang WW; Matlashewski G
    Vaccine; 2001 Oct; 20(1-2):59-66. PubMed ID: 11567746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis.
    Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R
    J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.
    Basu R; Bhaumik S; Basu JM; Naskar K; De T; Roy S
    J Immunol; 2005 Jun; 174(11):7160-71. PubMed ID: 15905560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis.
    Dole VS; Raj VS; Ghosh A; Madhubala R; Myler PJ; Stuart KD
    Vaccine; 2000 Oct; 19(4-5):423-30. PubMed ID: 11027804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LmjMAPK10 offers protection against Leishmania donovani infection.
    Kumar S; Zutshi S; Patidar A; Bodhale N; Roy S; Sarkar A; Saha B
    Parasite Immunol; 2020 Feb; 42(2):e12687. PubMed ID: 31770453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.
    Marques-da-Silva EA; Coelho EA; Gomes DC; Vilela MC; Masioli CZ; Tavares CA; Fernandes AP; Afonso LC; Rezende SA
    Parasitol Res; 2005 Dec; 98(1):67-74. PubMed ID: 16261353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
    Bhowmick S; Mazumdar T; Sinha R; Ali N
    J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.